ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation

References

• Mohamed AJ, Yu L, Bäckesjö C-M, Vargas L, Faryal R, Aints A, et al. Bruton’s tyrosine kinase (BTK): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58–73.
   PubMed Web of Science ®Google Scholar
• Lougaris V, Baronio M, Vitali M, Tampella G, Cattalini M, Tassone L, et al. Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. J Allergy Clin Immunol. 2014;133(6):1644–50.e4.
   PubMed Web of Science ®Google Scholar
• Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296(5573):1641–2.
   PubMed Web of Science ®Google Scholar
• Setoguchi R, Kinashi T, Sagara H, Hirosawa K, Takatsu K. Defective degranulation and calcium mobilization of bone-marrow derived mast cells from Xid and Btk-deficient mice. Immunol Lett. 1998;64(2–3):109–18.
   PubMed Web of Science ®Google Scholar
• Park H, Wahl MI, Afar DEH, Turck CW, Rawlings DJ, Tam C, et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity. 1996;4(5):515–25.
   PubMed Web of Science ®Google Scholar
• Baba Y, Hashimoto S, Matsushita M, Watanabe D, Kishimoto T, Kurosaki T, et al. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci USA. 2001;98(5):2582–6.
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity. 2000;12(1):1–5.
   PubMed Web of Science ®Google Scholar
• Petro JB, Rahman SMJ, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med. 2000;191(10):1745–54.
   PubMed Web of Science ®Google Scholar
• Campana D, Farrant J, Inamdar N, Webster AD, Janossy G. Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. J Immunol. 1990;145(6):1675–80.
   PubMed Web of Science ®Google Scholar
• Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol. 2006;118(2–3):195–200.
   PubMed Web of Science ®Google Scholar
• Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221–30.
   PubMed Web of Science ®Google Scholar
• Amoras AL, Kanegane H, Miyawaki T, Vilela MM. Defective Fc-, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients. J Investig Allergol Clin Immunol. 2003;13(3):181–8.
   PubMed Web of Science ®Google Scholar
• Sochorová K, Horváth R, Rozková D, Litzman J, Bartunková J, Sedivá A, et al. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood. 2007;109(6):2553–6.
   PubMed Web of Science ®Google Scholar
• Rawlings D, Saffran D, Tsukada S, Largaespada D, Grimaldi J, Cohen L, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science. 1993;261(5119):358–61.
   PubMed Web of Science ®Google Scholar
• Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, et al. Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3(3):283–99.
   PubMed Web of Science ®Google Scholar
• Hasan M, Lopez-Herrera G, Blomberg KEM, Lindvall JM, Berglöf A, Smith CIE, et al. Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton's tyrosine kinase-deficient mice. Immunology. 2008;123(2):239–49.
   PubMed Web of Science ®Google Scholar
• Fiedler K, Sindrilaru A, Terszowski G, Kokai E, Feyerabend TB, Bullinger L, et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood. 2011;117(4):1329–39.
   PubMed Web of Science ®Google Scholar
• Wang S-P, Iwata S, Nakayamada S, Niiro H, Jabbarzadeh-Tabrizi S, Kondo M, et al. Amplification of IL-21 signalling pathway through Bruton’s tyrosine kinase in human B cell activation. Rheumatology. 2015;54(8):1488–97.
   PubMed Web of Science ®Google Scholar
• Kil LP, de Bruijn MJW, van Nimwegen M, Corneth OBJ, van Hamburg JP, Dingjan GM, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012;119(16):3744–56.
   PubMed Web of Science ®Google Scholar
• Fujii T. Direct and indirect pathogenic roles of autoantibodies in systemic autoimmune diseases. Allergol Int. 2014;63(4):515–22.
   PubMed Web of Science ®Google Scholar
• Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther. 2008;10(4):R94.
   PubMed Web of Science ®Google Scholar
• Krupa A, Fol M, Rahman M, Stokes KY, Florence JM, Leskov IL, et al. Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2014;307(6):L435–48.
   PubMed Web of Science ®Google Scholar
• Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013;346(2):219–28.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075–80.
   PubMed Web of Science ®Google Scholar
• Schett G, Stolina M, Bolon B, Middleton S, Adlam M, Brown H, et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum. 2005;52(10):3192–201.
   PubMedGoogle Scholar
• Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 2008;132(5):794–806.
   PubMed Web of Science ®Google Scholar
• Steinberg EB, Santoro TJ, Chused TM, Smathers PA, Steinberg AD. Studies of congenic MRL-Ipr/Ipr.xid mice. J Immunol. 1983;131(6):2789–95.
   PubMed Web of Science ®Google Scholar
• Mina-Osorio P, LaStant J, Keirstead N, Whittard T, Ayala J, Stefanova S, et al. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. Arthritis Rheum. 2013;65(9):2380–91.
   PubMed Web of Science ®Google Scholar
• Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White)F1 but Not in BALB/c mice. J Immunol. 2005;174(5):2499–506.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science. 2005;308(5726):1318–21.
   PubMed Web of Science ®Google Scholar
• Watterson SH, De Lucca GV, Shi Q, Langevine CM, Liu Q, Batt DG, et al. Discovery of 6-fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of Bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers. J Med Chem. 2016;59(19):9173–200.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.
   PubMed Web of Science ®Google Scholar
• Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2015;88(1):74–9.
   PubMed Web of Science ®Google Scholar
• Benson MJ, Rodriguez V, von Schack D, Keegan S, Cook TA, Edmonds J, et al. Modeling the clinical phenotype of BTK inhibition in the mature murine immune system. J Immunol. 2014;193(1):185–97.
   PubMed Web of Science ®Google Scholar
• Vinuesa CG, Chang P-P. Innate B cell helpers reveal novel types of antibody responses. Nat Immunol. 2013;14(2):119–26.
   PubMed Web of Science ®Google Scholar
• Sen G, Khan AQ, Chen Q, Snapper CM. In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J Immunol. 2005;175(5):3084–91.
   PubMed Web of Science ®Google Scholar
• Bannoudi H, Ioan-Facsinay A, Toes REM, Bridging autoantibodies and arthritis: the role of Fc receptors. In: Daeron M, Nimmerjahn F, editors. Fc Receptors. Cham: Springer International Publishing; 2014. p. 303–19.
   Google Scholar
• Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122(5):1791–802.
   PubMed Web of Science ®Google Scholar
• Bolon B, Stolina M, King C, Middleton S, Gasser J, Zack D, et al. Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol. 2011;2011:569068.
   PubMedGoogle Scholar
• Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov. 2011;10(4):307–17.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kim T, Jeong D, Kim N, Choi Y. The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation. J Biol Chem. 2008;283(17):11526–34.
   PubMed Web of Science ®Google Scholar
• Shinohara M, Chang BY, Buggy JJ, Nagai Y, Kodama T, Asahara H, et al. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. Bone. 2014;60:8–15.
   PubMed Web of Science ®Google Scholar
• Halcomb KE, Musuka S, Gutierrez T, Wright HL, Satterthwaite AB. Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells. Mol Immunol. 2008;46(2):233–41.
   PubMed Web of Science ®Google Scholar
• Vogelpoel LTC, Baeten DLP, de Jong EC, den Dunnen J. Control of cytokine production by human Fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol. 2015;6:79.
   PubMed Web of Science ®Google Scholar
• Byrne JC, Ní Gabhann J, Stacey KB, Coffey BM, McCarthy E, Thomas W, et al. Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin. J Immunol. 2013;190(10):5207–15.
   PubMed Web of Science ®Google Scholar
• Licht R, Dieker JWC, Jacobs CWM, Tax WJM, Berden JHM. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun. 2004;22(2):139–45.
   PubMed Web of Science ®Google Scholar
• Ellmeier W, Jung S, Sunshine MJ, Hatam F, Xu Y, Baltimore D, et al. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J Exp Med. 2000;192(11):1611–24.
   PubMed Web of Science ®Google Scholar
• Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood. 2003;102(10):3592–9.
   PubMed Web of Science ®Google Scholar